HUTCHMED (China) (HMDCF) Finished Goods (2015 - 2026)
HUTCHMED (China)'s (HMDCF) quarterly Finished Goods came in at $15.7 million in Q2 2026, down 34.56% year-over-year from $24.0 million in Q2 2025, and down 15.83% quarter-over-quarter from $18.7 million in Q4 2025.
Analysis
HUTCHMED (China) (HMDCF) Finished Goods (2015 - 2026) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Finished Goods for 12 consecutive years, with $15.7 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Finished Goods fell 34.56% year-over-year to $15.7 million in Q2 2026; TTM through Jun 2026 was $15.7 million, a 34.56% decrease from a year earlier, with the FY2025 full-year figure at $18.7 million, down 28.3% from the prior year.
- Finished Goods was $15.7 million for Q2 2026 at HUTCHMED (China), down from $18.7 million in the prior quarter.
- Over five years, Finished Goods peaked at $29.3 million in Q4 2022 and troughed at $15.7 million in Q2 2026.
- A 5-year average of $23.3 million and a median of $24.0 million in 2025 frame the typical range for Finished Goods.
- Across the five-year window, Finished Goods jumped 47.09% in 2022 and plunged 34.56% in 2026, its largest moves.
- Over 5 years, Finished Goods stood at $29.3 million in 2022, then slipped by 19.88% to $23.5 million in 2023, then increased by 10.98% to $26.1 million in 2024, then retreated by 28.3% to $18.7 million in 2025, then slipped by 15.83% to $15.7 million in 2026.
- The last three Finished Goods figures came in at $15.7 million (Q2 2026), $18.7 million (Q4 2025), and $24.0 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 15.72 Mn |
| Dec 31, 2025 | 18.68 Mn |
| Jun 30, 2025 | 24.02 Mn |
| Dec 31, 2024 | 26.05 Mn |
| Jun 30, 2024 | 21.65 Mn |
| Dec 31, 2023 | 23.47 Mn |
| Jun 30, 2023 | 26.64 Mn |
| Dec 31, 2022 | 29.30 Mn |
| Jun 30, 2022 | 24.31 Mn |
| Dec 31, 2021 | 19.92 Mn |
| Jun 30, 2021 | 17.30 Mn |
| Dec 31, 2020 | 15.26 Mn |
| Jun 30, 2020 | 13.90 Mn |
| Dec 31, 2019 | 13.93 Mn |
| Sep 30, 2019 | 13.89 Mn |
| Jun 30, 2019 | 12.36 Mn |
| Mar 31, 2019 | 16.28 Mn |
| Dec 31, 2018 | 11.66 Mn |
| Jun 30, 2018 | 9.15 Mn |
| Dec 31, 2017 | 11.48 Mn |